Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences, discusses the development of a safer option to opioid pain killers that prevents abuse and overdose. Topics include Tripsin-Activated Abuse Protection, the MPAR approach to prevent prescription opioid overdose, and the advancement of a FDA approved product for chronic severe pain patients.